

#### **IDEA Workshop**

# Validity of the QRA Methodology & Possibilities of Further Refinement

March 11-13<sup>th</sup>, 2014

Dolce La Hulpe Brussels
Chaussée de Bruxelles, 135
B-1310 La Hulpe, Belgium

Tel: +32 (0)2 290 98 00, Fax: +32 (0)2 290 99 00

#### Final Draft Programme

#### Tuesday, March 11<sup>th</sup> - Workshop opening

All plenary lectures and discussions of this workshop will take place in the meeting room 'Teck'.

3:00 - 6:30 pm	Welcome and registration	
5:00 - 5:15	Workshop opening – Hans Bender and Matthias Vey	
5:15 - 6:15	Summary presentation of the Dermal Sensitization QRA and outcome of the first QRA workshop (March 19-20 <sup>th</sup> , 2013)  Speaker: Anne Marie Api	
6:30 - 9:30	Standing buffet (Oak bar, Dolce La Hulpe)	

### Wednesday, March 12<sup>th</sup> (9:00 am to 6:00 pm) – Day 1 (Presentations and plenary discussion)

First session – Refinement of the QRA SAF (Sensitization Assessment Factors)

9:00 - 9:30 am (Re-)consideration of the underlying science

Speaker: David Basketter

9:30 - 10:00 Practical considerations in defining the SAFs

Speaker: Bob Safford

**IDEA Management Team** 

Avenue des Arts, 6 1210 Brussels, Belgium Tel: +32-2 214 20 61 Fax: +32-2 214 20 69

www.ideaproject.info



national Dialogue for the Evaluation of Allerge	ns		
10:00 - 11:00	Questions and discussion		
11:00 - 11:15	Coffee break		
Second session –	Refinement of the exposure assessment		
11:15 - 11:35	Re-introduction of the RIFM/Creme exposure model  Speaker: Cronan Mc Namara (and introduction by Anne Marie Api)		
11:35 - 12:05	Incorporating aggregate exposure in the QRA  Speaker: Bob Safford (and follow-up on exposure by Anne Marie Api)		
12:05 – 1:00 pm	Questions and discussion		
1:00 – 1:45	Lunch		
Third session – M	easure of the QRA effectiveness		
1:45 – 2:10	Prospective and retrospective studies  Speaker: Anne Marie Api		
2:10 – 2:40	Questions and discussion		
Fourth session – C	<u>Communication</u>		
2:40 – 2:50	Impact of the first IDEA workshop on the IFRA Standards development process  Speaker: Matthias Vey		
2:50 – 3:00	Towards a revamped IFRA compliance program  Speaker: Matthias Vey / Fred Lebreux		
3:00 – 3:10	The scope of the QRA as applied by IFRA. Informing Regulators and unregulated sectors about the risks of contact allergy to fragrance allergens  Speaker: Matthias Vey / Fred Lebreux		
3:10 – 3:30	Questions and discussion		
3:30 – 4:00	Coffee break		
Fifth session – Ple	enary discussion		
4:00 – 4:20	Preliminary progress report		

Speaker: Rapporteur of the workshop



4:20 – 5:30	Evaluation of what was presented on Day 1
5:30 - 6:00	End of Day 1

6:30 – 9:30 Reception followed by a dinner (Brasserie 135, Dolce La Hulpe)

## Thursday, March 13<sup>th</sup> (9:00 am to 4:30 pm) – Day 2 (Open discussion)

9:00 – 9:30 am	Adoption of the agenda and wrap-up of Day 1		
9:30 – 12:30	The participants will be subdivided into three working groups:		
Meeting Room	Theme		
Teck (1 <sup>st</sup> floor)	Working group 1 – Theme and participants to be agreed at the end of Day 1  Working group Rapporteur: to be determined		
Ebene (ground floor)	Working group 2 – Theme and participants to be agreed at the end of Day 1  Working group Rapporteur: to be determined		
Delfino (ground floor)	Working group 3 – Theme and participants to be agreed at the end of Day 1 Working group Rapporteur: to be determined		
12:30 – 1:15	Lunch		
1:15 – 3:00 pm	Presentation of the conclusions / recommendations of the three working groups and establishment of priorities.		
3:00 – 3:15	Coffee break		
3:15 – 4:30	Conclusions of the workshop and next steps		
4:30 pm	End of Day 2 and workshop closing		



#### List of participants (37):

Dr.	Jay	Ansell	PCPC (Observer), USA
Dr.	Eric	Antignac	L'Oréal, France
Dr.	Anne Marie	Api	RIFM, USA
Dr.	David	Basketter	RIFM Consultant, UK
Prof.	Donald	Belsito	Columbia University Medical Center and REXPAN Member, USA
Dr.	Hans-J.	Bender	Consultant (Moderator), Germany
Prof.	James	Bridges	Chairman of the IDEA Supervisory Group (Rapporteur), UK
Prof.	Magnus	Bruze	Lunds Universiteit and REXPAN Member, Sweden
Dr.	Dagmar	Bury	L'Oréal
Dr.	Peter	Cadby	Chanel, France
Dr.	Gaetano	Castaldo	EU Commission – DG Sanco – Risk Management Unit, Belgium
Dr.	Federica	de Gaetano	EU Commission – DG Sanco – Risk Management Unit, Belgium
Prof.	Thomas	Diepgen	Ruprecht-Karls University, Germany
Dr.	Janine	Ezendam	RIVM, The Netherlands
Dr.	Peter	Friedmann	University of Southampton, UK
Prof.	David	Gawkrodger	Royal Hallamshire Hospital and Vice-chairman of the SCCS, UK
Dr.	Nicola	Gilmour	Unilever, UK
Dr.	Peter	Griem	Symrise, Germany
Dr.	Etje	Hulzebos	I.F.F., The Netherlands
Dr.	Petra	Kern	Procter & Gamble, China
Dr.	Christine	Lafforgue	Université Paris sud 11, France
Dr.	Christeine	Lally	P&G, Belgium
Dr.	Fred	Lebreux	IFRA (IDEA Management Team), Belgium
Dr.	Sylvie	Lemoine	A.I.S.E., Belgium
Dr.	Cronan	McNamara	Crème Global, Ireland
Dr.	Andreas	Natsch	Givaudan, Switzerland
Prof.	David	Roberts	Liverpool John Moores University, UK
Prof.	Vera	Rogiers	Vrije Universiteit Brussel, Belgium
Dr.	Bob	Safford	RIFM Consultant, UK
Dr.	Joanne	Salverda	RIVM, The Netherlands
Dr.	Florian	Schellauf	Cosmetics Europe (Observer), Belgium
Dr.	Scott	Schneider	Firmenich, USA
Prof.	Axel	Schnuch	IVDK / University of Göttingen, Germany
Mr.	Pierre	Sivac	IFRA (Observer), Belgium
Ms.	Izabela	Taborska	EU Commission – DG Sanco – Risk Management Unit, Belgium
Dr.	Matthias	Vey	IFRA (IDEA Management Team), Belgium

Guy's & St Thomas' NHS Hospitals, UK

White

Dr.

lan